Navepegritide combined with lonapegsomatropin for the treatment of children with achondroplasia: 52-week results from the phase 2 COACH trial
Navepegritide kombiniert mit Lonapegsomatropin zur Behandlung von Kindern mit Achondroplasie: 52-Wochen-Ergebnisse der Phase-2-COACH-Studie
European Journal of Endocrinology · 01.06.2026 · 194 (6) · 745-755
DOI: 10.1093/ejendo/lvag082 ↗Auf einen Blick
In der Phase-2-COACH-Studie erhielten Kinder mit Achondroplasie wöchentlich Navepegritide und Lonapegsomatropin. Nach 52 Wochen zeigte sich eine höhere Wachstumsgeschwindigkeit als unter Navepegritide-Monotherapie.
Fragestellung
Verbessert die Kombination aus Navepegritide und Lonapegsomatropin das Wachstum bei Kindern mit Achondroplasie im Vergleich zu Navepegritide allein?
Methode
Proof-of-concept-Phase-2-Studie bei Kindern mit Achondroplasie im Alter von 2 bis 11 Jahren; wöchentliche Gabe von Navepegritide und Lonapegsomatropin; Vergleich mit Navepegritide-Monotherapie aus der ApproaCH-Studie.
Ergebnisse
21 Kinder eingeschlossen: 12 treatment-naive und 9 navepegritide-experienced. TN: AGV 8,69 cm/Jahr vs. 5,95 cm/Jahr; Differenz 2,74 cm/Jahr (P < .0001). Unerwünschte Ereignisse meist mild, keine Abbrüche.
Schlussfolgerung der Autor:innen
Die Ergebnisse sprechen laut Autor:innen dafür, dass Navepegritide die Wachstumsplatte stärker für den Effekt von Lonapegsomatropin empfänglich machen kann.
Kernaussagen
- AGV nach 52 Wochen unter Kombination höher als unter Monotherapie
- TN: 8,69 vs. 5,95 cm/Jahr; Differenz 2,74 cm/Jahr
- Verträglichkeit gut; keine Behandlungsabbrüche
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Endocrinology, online erschienen am 18.05.2026. Verfasst von Ciara M McDonnell und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Children's Health Ireland at Temple Street, Dublin 1 D01 XD99, Ireland. Hauptthemen laut MEDLINE: Achondroplasia, Human Growth Hormone, Natriuretic Peptide, C-Type. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ascendis Pharma, Inc..
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objective
Navepegritide, a prodrug of C-type natriuretic peptide, has demonstrated improved growth and additional benefits, including lower limb alignment, in children with achondroplasia. The well-described mechanism of action of navepegritide in the growth plate is hypothesized to enhance its receptivity to lonapegsomatropin, a prodrug of somatropin, to provide benefits beyond those seen with monotherapies in achondroplasia.
Methods
In the proof-of-concept phase 2 COACH trial, children with achondroplasia aged 2 to 11 received weekly navepegritide and lonapegsomatropin. The primary efficacy endpoint was annualized growth velocity (AGV) at week 52 vs AGV with navepegritide monotherapy in the ApproaCH trial (NCT05598320).
Results
Twenty-one children were enrolled: 12 received no prior growth-promoting treatment (treatment-naive, TN) and 9 had been receiving navepegritide monotherapy for >1 year (navepegritide-experienced, NE). At week 52, TN children receiving navepegritide and lonapegsomatropin had a least squares mean AGV of 8.69 cm/year versus 5.95 cm/year for matched children who received navepegritide monotherapy, a difference of 2.74 cm/year (P < .0001). Observed mean AGV for TN children was 8.80 cm/year, a +3.89 cm/year increase from baseline (P = .0015). NE children had an observed mean AGV of 8.42 cm/year, a +3.28 cm/year increase from navepegritide-treated baseline (P < .0001). An improvement in body proportionality was observed and arm span increased substantially (+9.4 cm in TN and +7.9 cm in NE children), in line with gains in height. Treatments were well-tolerated with generally mild adverse events and no treatment discontinuations.
Conclusions
In this prospective trial, the robust growth and anthropometric results suggest that by continuously relieving the pre-hypertrophic block in achondroplasia, navepegritide may make the growth plate more responsive to the strong complementary effect of lonapegsomatropin. Trial registration details ClinicalTrials.gov NCT06433557
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Children's Health Ireland at Temple Street, Dublin 1 D01 XD99, Ireland.
- Discipline of Paediatrics, University of Dublin, Trinity College, Dublin D02 PN40, Ireland.
- Guy's and St.Thomas' NHS Foundation Trust, Evelina Children's Hospital, London SE1 7EH, United Kingdom.
- Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
- Clinical Development, Ascendis Pharma LLC, Palo Alto, CA 94304, United States.
- Ascendis Pharma, A/S, 2900 Hellerup, Denmark.
Förderung
- Ascendis Pharma, Inc.
Zitieren
APA
McDonnell, C. M., Irving, M., Nolting, L. A., Abdelrahman, S. G., Dalby, L. W., Iklé, J. M., Jensen, S. M., Komirenko, A. S., Ominsky, M. S., Shu, A. D., & Hove, H. B. (2026). Navepegritide combined with lonapegsomatropin for the treatment of children with achondroplasia: 52-week results from the phase 2 COACH trial. European Journal of Endocrinology, 194(6), 745-755. https://doi.org/10.1093/ejendo/lvag082
Vancouver
McDonnell CM, Irving M, Nolting LA, Abdelrahman SG, Dalby LW, Iklé JM, et al. Navepegritide combined with lonapegsomatropin for the treatment of children with achondroplasia: 52-week results from the phase 2 COACH trial. European Journal of Endocrinology. 2026;194(6):745-755. doi:10.1093/ejendo/lvag082
BibTeX
@article{McDonnell2026,
author = {McDonnell, Ciara M and Irving, Melita and Nolting, Line Aagaard and Abdelrahman, Sohair G and Dalby, Lene Worsaae and Iklé, Jennifer M and Jensen, Simon Mejlhede and Komirenko, Allison S and Ominsky, Michael S and Shu, Aimee D and Hove, Hanne B},
title = {Navepegritide combined with lonapegsomatropin for the treatment of children with achondroplasia: 52-week results from the phase 2 COACH trial},
journal = {European Journal of Endocrinology},
year = {2026},
volume = {194},
number = {6},
pages = {745--755},
doi = {10.1093/ejendo/lvag082}
}
EUVIMED